“We are aware, and it’s very concerning,” said Alliance for Substance Abuse Progress Executive Director Sherri Jewett. “…Those are just not people that we think about dying of overdoses.

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

An old drug has taken on new popularity — and it has doctors concerned. “We walk into the president's chambers (at the fraternity) … and there’s three dudes carrying, like, Butane tanks ...

New Jersey’s Indiscriminate Prosecution of Children as Adults,” reveals that prosecutors have near-total discretion to decide ...

The RewinD-LB trial's double-blind phase did not show significant differences between the drug, dosed at 40mg three times daily, and the placebo group over 16 weeks. However, pharmacokinetic data ...

It's about that mystery substance that found its way onto County Road 104 just east of Silver Hill last November. It splashed up on dozens of cars, where it hardened, ruining paint jobs and brake ...

The company, previously known as Psych Capital plc, has completed key preclinical activities for its psilocybin-based drug aimed at treating eating disorders, specifically anorexia nervosa.

8 Goal Setting Templates for Making Real Progress in 2025 Your email has been ... and comment to leave notes for yourself. If you’re looking to plan and manage goals longer term, this template ...

A Daily Progress request for more information regarding the nature of the note went unanswered, and the Orange County School Board did not discuss the note in open session at its meeting Monday.

But that is a real possibility under President Donald Trump, whose threat to invoke the Insurrection Act raises the specter of unchecked violence and abuse of power that puts our democracy at risk ...

Challenging as it might seem, treating serious mental health conditions and substance use disorders is not like treating a cold or infection. People require long-term treatment, supportive housing ...

Drs Harrington and Gibson review their picks for the top cardiology trials of 2024 and look ahead to 2025, particularly what health topics may be prioritized by the new administration.